Breaking News Instant updates and real-time market news.

CVS

CVS Health

$55.39

0.57 (1.04%)

, CI

Cigna

$160.51

0.81 (0.51%)

07:29
07/11/19
07/11
07:29
07/11/19
07:29

Trump administration withdraws proposal to end drug rebates, Politico reports

The Trump administration has withdrawn its proposal to eliminate rebates from government drug plans, a White House spokesperson confirmed to Politico, Dan Diamond and Adam Cancryn report. Spokesperson Judd Deere said in a statement, "Based on careful analysis and thorough consideration, the president has decided to withdraw the rebate rule. The Trump administration is encouraged by continuing bipartisan conversations about legislation to reduce outrageous drug costs imposed on the American people, and President Trump will consider using any and all tools to ensure that prescription drug costs will continue to decline." Publicly traded companies in the pharmacy benefit management space include CVS Health (CVS), Cigna (CI) and UnitedHealth (UNH).

CVS

CVS Health

$55.39

0.57 (1.04%)

CI

Cigna

$160.51

0.81 (0.51%)

UNH

UnitedHealth

$247.48

1.47 (0.60%)

  • 18

    Jul

  • 01

    Aug

  • 07

    Aug

  • 09

    Sep

CVS CVS Health
$55.39

0.57 (1.04%)

06/18/19
JEFF
06/18/19
NO CHANGE
Target $58
JEFF
Buy
CVS Health share upside limited on lack of catalysts, says Jefferies
Jefferies analyst Brian Tanquilut believes the "muted" reaction to CVS Health's recent articulation of its planned strategic moves and issuance of guidance thru 2022 underscore the "show-me stance" investors continue to take on the name. The analyst does not see any meaningful near-term catalysts that could drive "significant" stock upside over the next 12 months. That said, the stock's downside is "limited by a discounted valuation," Tanquilut tells investors in a research note. He keeps raised his price target for CVS Health to $58 from $57 and keeps a Hold rating on the name.
06/20/19
JEFF
06/20/19
NO CHANGE
JEFF
Amazon's PillPack looking to bypass PBMs, says Jefferies
Jefferies analyst Brian Tanquilut says his review of documents related to a case filed by CVS Health (CVS), which seeks to prevent a former CVS executive from joining PillPack, shows that Amazon.com (AMZN) is seeking to develop a service offering that would bypass pharmacy benefit managers and contract directly with payors. While it is difficult to predict the success of PillPack's efforts to bypass existing prescription payment structures, the court disclosure is a potential negative for PBMs like CVS Health, UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI), Tanquilut tells investors in a research note.
06/05/19
STPT
06/05/19
UPGRADE
STPT
Buy
CVS Health upgraded to Buy from Hold at Standpoint Research
06/25/19
TIGR
06/25/19
NO CHANGE
TIGR
Tigress Financial sees 'significant upside' in CVS Health
Tigress Financial analyst Ivan Feinseth reiterated a Buy rating on CVS Health, citing the ongoing strength in Pharmacy Services, as well as Retail/LTC growth that continues to drive accelerating business performance. Feinseth sees significant upside in the shares and continues to recommend purchase.
CI Cigna
$160.51

0.81 (0.51%)

06/03/19
SBSH
06/03/19
NO CHANGE
Target $203
SBSH
Buy
Cigna price target lowered to $203 from $228 at Citi
Citi analyst Ralph Giacobbe lowered his price target for Cigna to $203 from $228 to reflect the recent "re-rating" of the managed care group. Cigna is now a "show me" story that will take some time, Giacobbe tells investors in a research note. The analyst, however, remains bullish on the shares following the company's analyst day and he keeps a Buy rating on the name.
06/25/19
SBSH
06/25/19
NO CHANGE
SBSH
Molina, Centene have most at stake from Texas Medicaid awards, says Citi
Citi analyst Ralph Giacobbe noted that Texas' "highly anticipated" STAR+PLUS contract for the states' higher acuity Medicaid members is expected to be awarded this Friday, June 28. Among the incumbents in the state, Molina (MOH) and Centene (CNC) have the most at stake, as their respective STAR+PLUS earnings contribute about 7% and 2%, respectively, of his and consensus estimates, Giacobbe tells investors. He estimates that the other incumbents - Anthem (ANTM), Cigna (CI) and UnitedHealth (UNH) - have 1% or less of their earnings at stake, adding that investor expectations are for the incumbents to largely retain business.
05/16/19
COWN
05/16/19
NO CHANGE
COWN
Move lower in managed care stocks appears overdone, says Cowen
Cowen analyst Charles Rhyee lowered his target multiple for the managed care group slightly from recent historical levels, but said he believes the recent weakness in the space on concerns around "Medicare for All," the rebate rule and the Texas ACA decision appears overdone. The discount for managed care stocks relative to the broader market has risen to a multi-year high, but he argues that underlying market fundamentals are stronger than in the pre-ACA era and Rhyee contends that there is "still plenty of growth left" in the managed care space, particularly in government-sponsored business. Stocks in the group include Anthem (ANTM), Cigna (CI), Centene (CNC), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
UNH UnitedHealth
$247.48

1.47 (0.60%)

07/08/19
BOFA
07/08/19
NO CHANGE
Target $75
BOFA
Neutral
Inspire Medical price target raised to $75 from $65 at BofA/Merrill
BofA/Merrill analyst Bob Hopkins raised his price target for Inspire Medical (INSP) to $75 from $65 after the company announced that United Healthcare (UNH) will provide coverage for Inspire's obstructive sleep apnea therapy as of August 1. In a research note to investors, Hopkins, who maintains a Neutral rating on Inspire, says it takes about 2-4 months for a patient insured by United to work their way through the prior-authorization, but Inspire now estimates that it will take just five days to get approval if a patient meats the restrictions set by United. Hopkins sees potential upside to Street numbers later in 2019 and 2022, but believes his positive outlook is largely reflected in the current stock price.
06/24/19
ADAM
06/24/19
NO CHANGE
Target $39
ADAM
Buy
HMS Holdings' recent weakness overdone, says Canaccord
Canaccord analyst Richard Close said he believes the recent weakness in HMS Holdings (HMSY) shares is overdone. The weakness was attributed to reports UnitedHealth (UNH) will be buying Equian, a payment integrity services provider. The analyst believes the pullback was based on fears of increased competition and potential risk that HMS will lose UnitedHealth as a customer. He said although both provide integrity services to healthcare, Equian does not provide COB services, which accounted for 66.4% of HMS's revenue. As a result, he does not believe this transaction should raise any concerns. Close reiterated his Buy rating and $39 price target on HMS Holdings shares.
06/21/19
CANT
06/21/19
NO CHANGE
CANT
Overweight
HMS Holdings selloff on Equian deal report overdone, says Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper noted HMS Holdings (HMSY) shares are lower, which he believes is due to media reports that UnitedHealth (UNH) will acquire privately-held Equian, which is focused primarily on payment integrity. Halper notes that payment integrity accounts for about 19% of HMS' total revenue and said any potential transaction could result in health plans switching from Equian to HMS over time. The analyst, who views the selloff as overdone, keeps an Overweight rating on HMS Holdings shares.

TODAY'S FREE FLY STORIES

UAL

United Continental

$94.00

2.7 (2.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United Continental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

CCCL

China Ceramics

$0.87

(0.00%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
China Ceramics receives Nasdaq notification of non-compliance »

China Ceramics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$94.00

2.7 (2.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
United Continental reports Q2 total passenger revenue up 6.1% y/y »

Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

UAL

United Continental

$94.00

2.7 (2.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Earnings
United Continental reports Q2 adjusted EPS $4.21, consensus $4.08 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

VNDA

Vanda Pharmaceuticals

$13.45

-0.13 (-0.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
Vanda Pharmaceuticals announces study results for tradipitant »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

STIM

Neuronetics

$12.65

-0.2 (-1.56%)

, UNH

UnitedHealth

$264.60

-1.31 (-0.49%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Recommendations
Neuronetics, UnitedHealth analyst commentary  »

UnitedHealth coverage…

STIM

Neuronetics

$12.65

-0.2 (-1.56%)

UNH

UnitedHealth

$264.60

-1.31 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CTAS

Cintas

$239.46

-3.85 (-1.58%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Earnings
Cintas sees FY20 EPS $8.30-$8.45, consensus $8.32 »

Sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

UAL

United Continental

$94.00

2.7 (2.96%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Earnings
United Continental raises FY19 adj. EPS view to $10.50-$12.00, consensus $11.33 »

Prior view was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTAS

Cintas

$239.46

-3.85 (-1.58%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Earnings
Cintas reports Q4 EPS ex-items $2.07, consensus $1.93 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

CSX

CSX

$79.57

1.05 (1.34%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Hot Stocks
CSX says merchandise growth 'offset' intermodal weakness »

Chemicals increased as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

PETX

Aratana Therapeutics

$4.94

-0.11 (-2.18%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Hot Stocks
Aratana Therapeutics shareholders vote to adopt merger with Elanco Animal Health »

Aratana Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$94.00

2.7 (2.96%)

16:15
07/16/19
07/16
16:15
07/16/19
16:15
Earnings
United Continental reports Q2 adjusted EPS $4.21, consensus $4.08 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

KSFTF

Kingsoft

$0.00

(0.00%)

16:15
07/16/19
07/16
16:15
07/16/19
16:15
Downgrade
Kingsoft rating change  »

Kingsoft downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$79.68

1.16 (1.48%)

16:13
07/16/19
07/16
16:13
07/16/19
16:13
Hot Stocks
CSX reports Q2 operating ratio fell to 57.4% since Q2 last year »

Last year's Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

PDD

Pinduoduo

$20.13

0.77 (3.98%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Downgrade
Pinduoduo rating change  »

Pinduoduo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCBS

Nicolet Bankshares

$62.76

0.13 (0.21%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Earnings
Nicolet Bankshares reports Q1 EPS $1.91 with items, consensus $1.09 »

During Q2, Nicolet sold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$41.65

-1.39 (-3.23%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Downgrade
Weibo rating change  »

Weibo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRP

Ctrip

$36.88

-0.47 (-1.26%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Upgrade
Ctrip rating change  »

Ctrip upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$79.67

1.15 (1.46%)

16:11
07/16/19
07/16
16:11
07/16/19
16:11
Hot Stocks
CSX falls 6% after reporting Q2 results below expectations »

CSX shares are trading at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

SENS

Senseonics

$1.68

-0.075 (-4.29%)

16:10
07/16/19
07/16
16:10
07/16/19
16:10
Syndicate
Senseonics announces $80M convertible senior notes offering »

Senseonics Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

GALXF

Galaxy Resources

$0.00

(0.00%)

16:10
07/16/19
07/16
16:10
07/16/19
16:10
Downgrade
Galaxy Resources rating change  »

Galaxy Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INO

Inovio

$2.99

0.04 (1.36%)

16:09
07/16/19
07/16
16:09
07/16/19
16:09
Hot Stocks
Inovio to reduce annual burn rate by 25% and workforce by 28% »

Inovio Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SENS

Senseonics

$1.68

-0.075 (-4.29%)

16:08
07/16/19
07/16
16:08
07/16/19
16:08
Syndicate
Senseonics announces $25M common stock offering »

Senseonics Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.